These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Influence of chelate conjugation on a newly identified tumor-targeting peptide. Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241 [TBL] [Abstract][Full Text] [Related]
24. Improved synthesis and biological evaluation of chelator-modified α-MSH analogs prepared by copper-free click chemistry. Baumhover NJ; Martin ME; Parameswarappa SG; Kloepping KC; O'Dorisio MS; Pigge FC; Schultz MK Bioorg Med Chem Lett; 2011 Oct; 21(19):5757-61. PubMed ID: 21873053 [TBL] [Abstract][Full Text] [Related]
25. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. Goodwin DA; Meares CF; Osen M J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294 [TBL] [Abstract][Full Text] [Related]
26. Regressive DOTA labelling performance with indium-111 and yttrium-90 over a week of use. Hainsworth JE; Mather SJ Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1348. PubMed ID: 16142470 [No Abstract] [Full Text] [Related]
27. Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy. Chong HS; Ma X; Le T; Kwamena B; Milenic DE; Brady ED; Song HA; Brechbiel MW J Med Chem; 2008 Jan; 51(1):118-25. PubMed ID: 18062661 [TBL] [Abstract][Full Text] [Related]
28. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420 [TBL] [Abstract][Full Text] [Related]
29. Preparation and pharmacokinetics of samarium(III)-153-labeled DTPA-bis-biotin. Characterization and theoretical studies of the samarium(III)-152 conjugate. Ferro-Flores G; Ramírez FD; Tendilla JI; Pimentel-González G; Murphy CA; Meléndez-Alafort L; Ascencio JA; Croft BY Bioconjug Chem; 1999; 10(5):726-34. PubMed ID: 10502337 [TBL] [Abstract][Full Text] [Related]
30. Pyclen Tri-n-butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to (90)Y Radiolabeling. Le Fur M; Beyler M; Lepareur N; Fougère O; Platas-Iglesias C; Rousseaux O; Tripier R Inorg Chem; 2016 Aug; 55(16):8003-12. PubMed ID: 27486673 [TBL] [Abstract][Full Text] [Related]
31. Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid and biotin before radiolabeling. Wang Z; Mårtensson L; Nilsson R; Bendahl PO; Lindgren L; Ohlsson T; Sjögren HO; Strand SE; Tennvall J Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7171s-7177s. PubMed ID: 16203818 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. Foulon CF; Alston KL; Zalutsky MR Bioconjug Chem; 1997; 8(2):179-86. PubMed ID: 9095358 [TBL] [Abstract][Full Text] [Related]
33. DOTAGA-anhydride: a valuable building block for the preparation of DOTA-like chelating agents. Bernhard C; Moreau M; Lhenry D; Goze C; Boschetti F; Rousselin Y; Brunotte F; Denat F Chemistry; 2012 Jun; 18(25):7834-41. PubMed ID: 22615050 [TBL] [Abstract][Full Text] [Related]
34. Enhancement of reaction conditions for the radiolabelling of DOTA-peptides with high activities of yttrium-90. Nardelli A; Castaldi E; Ortosecco G; Speranza A; Storto G; Pace L; Salvatore M Appl Radiat Isot; 2011 Jan; 69(1):52-5. PubMed ID: 20869877 [TBL] [Abstract][Full Text] [Related]
35. Novel DOTA-based prochelator for divalent peptide vectorization: synthesis of dimeric bombesin analogues for multimodality tumor imaging and therapy. Abiraj K; Jaccard H; Kretzschmar M; Helm L; Maecke HR Chem Commun (Camb); 2008 Jul; (28):3248-50. PubMed ID: 18622433 [TBL] [Abstract][Full Text] [Related]
36. The humoral immune response to macrocyclic chelating agent DOTA depends on the carrier molecule. Perico ME; Chinol M; Nacca A; Luison E; Paganelli G; Canevari S J Nucl Med; 2001 Nov; 42(11):1697-703. PubMed ID: 11696642 [TBL] [Abstract][Full Text] [Related]
37. Investigations of N-linked macrocycles for 111In and 90Y labeling of proteins. Wu C; Virzi F; Hnatowich DJ Int J Rad Appl Instrum B; 1992 Feb; 19(2):239-44. PubMed ID: 1601676 [TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin. Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535 [TBL] [Abstract][Full Text] [Related]
39. Synthesis of a new NIR fluorescent Nd complex labeling agent. Aita K; Temma T; Shimizu Y; Kuge Y; Seki K; Saji H J Fluoresc; 2010 Jan; 20(1):225-34. PubMed ID: 19821013 [TBL] [Abstract][Full Text] [Related]
40. Conjugation of DOTA-like chelating agents to peptides and radiolabeling with trivalent metallic isotopes. Sosabowski JK; Mather SJ Nat Protoc; 2006; 1(2):972-6. PubMed ID: 17406332 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]